pharma news today glp-1 obesity drug Wegovy Pill Wins FDA Approval as First Oral Treatment for and Weight Loss intent:problem-solver GLP-1, GIP, and dual Medication:Tirzepatide (GLP-1 + GIP)

pharma news today glp-1 obesity drug Wegovy Pill Wins FDA Approval as First Oral Treatment for and Weight Loss intent:problem-solver GLP-1, GIP, and dual Medication:Tirzepatide (GLP-1 + GIP)

GLP-1, GIP, and dual agonist medications are all part of the incretin class. But they are not interchangeable. GLP-1 receptor agonists like semaglutide reduce appetite, slow digestion, stimulate insulin, and suppress excess

Since tirzepatide impacts GLP-1 and GIP it produces better results for weight loss

intent:problem-solver

Medication:Tirzepatide (GLP-1 + GIP)

Cosmos Study November 19, 2024 Dual-Team Study Team A:Dave Little, MDJoe Deckert, PhD Team B:Kersten Bartelt, RNJoe Longo Key Findings Patients with hypothyroidism who lose more than five pounds after starting a GLP-1 medication experience on average a 0.36 mU/L to 0.55 mU/L reduction of their thyroid-stimulating hormone (TSH) levels